PMID- 23982266
OWN - NLM
STAT- MEDLINE
DCOM- 20140928
LR  - 20171116
IS  - 1758-1001 (Electronic)
IS  - 0004-5632 (Linking)
VI  - 51
IP  - Pt 2
DP  - 2014 Mar
TI  - Soluble form of receptor for advanced glycation end-products (sRAGE): do sRAGE 
      ligands or anti-sRAGE auto-antibodies interfere with sRAGE quantification?
PG  - 248-57
LID - 10.1177/0004563213493402 [doi]
AB  - BACKGROUND: The soluble form of the receptor for advanced glycation end-products 
      (sRAGE) has been studied in various diseases. It is not clear why sRAGE levels 
      vary between studies, with controversial results. What also remains to be 
      determined is whether receptor for advanced glycation end-products (RAGE) ligands 
      could affect sRAGE assessment by epitope masking. Recently described anti-sRAGE 
      autoantibodies may play an interfering role. The aim of this study was therefore 
      to investigate the influence of RAGE ligands and anti-sRAGE autoantibodies on 
      sRAGE quantification. METHODS: The RAGE ligands carboxymethyllysine (CML; AGEs 
      with a high affinity for RAGE), S100 proteins, high-mobility group protein B1 
      (HMGB1) and beta-amyloid peptide (abeta) were tested by enzyme-linked immunosorbent 
      assay (ELISA) with recombinant sRAGE (rHu-sRAGE) or serum from healthy controls. 
      Using ELISA, anti-sRAGE autoantibodies (IgGs) were identified in haemodialysis 
      (HD) patients, then purified and incubated with rHu-sRAGE or serum to investigate 
      their effects on sRAGE levels. RESULTS: RAGE ligands, either alone at three 
      different concentrations (CML was also tested at different glycation levels) or a 
      mixture of all these ligands, did not affect sRAGE levels when incubated with 
      rHu-sRAGE or control serum. Compared with healthy controls, HD patients had 
      higher levels of sRAGE (P < 0.001) and anti-sRAGE IgGs (P < 0.05). However, 
      incubation of rHu-sRAGE with purified IgGs from HD patients had no effect on 
      sRAGE quantification. CONCLUSIONS: RAGE ligands or anti-sRAGE autoantibodies did 
      not interfere with sRAGE quantification. Further studies are required to 
      elucidate the variability in sRAGE levels reported in the literature and to 
      define the potential of sRAGE for use as a reliable biomarker.
FAU - Lorenzi, Rodrigo
AU  - Lorenzi R
AD  - Department of Vascular Aging Biology, Blood-Vessel Interface and Vascular Repair 
      Unit, Lille School of Medicine, Lille2 University, Lille, France.
FAU - Grossin, Nicolas
AU  - Grossin N
FAU - Lambert, Marc
AU  - Lambert M
FAU - Daroux, Maite
AU  - Daroux M
FAU - Adjoutah, Zoubir
AU  - Adjoutah Z
FAU - Flahaut, Christophe
AU  - Flahaut C
FAU - Jacolot, Philippe
AU  - Jacolot P
FAU - Tessier, Frederic J
AU  - Tessier FJ
FAU - Lefranc, Didier
AU  - Lefranc D
FAU - Desremaux, Pierre
AU  - Desremaux P
FAU - Dubucquoi, Sylvain
AU  - Dubucquoi S
FAU - Boulanger, Eric
AU  - Boulanger E
LA  - eng
PT  - Journal Article
DEP - 20130827
PL  - England
TA  - Ann Clin Biochem
JT  - Annals of clinical biochemistry
JID - 0324055
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Ligands)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, Immunologic)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Artifacts
MH  - Autoantibodies/*immunology
MH  - Enzyme-Linked Immunosorbent Assay/*methods
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/immunology
MH  - Ligands
MH  - Male
MH  - Middle Aged
MH  - Protein Structure, Tertiary
MH  - Receptor for Advanced Glycation End Products
MH  - Receptors, Immunologic/*analysis/chemistry/immunology/*metabolism
MH  - Renal Dialysis
MH  - Solubility
OTO - NOTNLM
OT  - Quality assurance & control
OT  - clinical studies
OT  - immunoassay
OT  - laboratory methods
EDAT- 2013/08/29 06:00
MHDA- 2014/10/01 06:00
CRDT- 2013/08/29 06:00
PHST- 2013/08/29 06:00 [entrez]
PHST- 2013/08/29 06:00 [pubmed]
PHST- 2014/10/01 06:00 [medline]
AID - 0004563213493402 [pii]
AID - 10.1177/0004563213493402 [doi]
PST - ppublish
SO  - Ann Clin Biochem. 2014 Mar;51(Pt 2):248-57. doi: 10.1177/0004563213493402. Epub 
      2013 Aug 27.